Big Pharma's Greed: Patients Suffer Amid Corruption Scandal
Submitted by MAGA
Posted 3 hours ago
Astonishing allegations of corruption and betrayal have emerged from the biopharmaceutical industry, spotlighting the increasingly dangerous exploitation of patients by powerful corporate entities.
Patrick Girondi, the founder of San Rocco Therapeutics (SRT), has launched a fierce campaign against corporate giants in Big Pharma, claiming that they are obstructing groundbreaking advances in gene therapy for sickle cell disease and thalassemia.
In a recent meeting with Health and Human Services Secretary Robert F. Kennedy Jr. and FDA officials, Girondi detailed a conspiracy to suppress his innovative and affordable gene therapy solutions—efforts which he argues have cost both lives and financial stability over the years.
According to Girondi, the industry's greed is jeopardizing the health of countless patients who could benefit from his treatments.
He accuses notable figures in the pharmaceutical sector, including former Bluebird Bio CEO Nick Leschly, of misappropriation and sabotaging SRT’s potential to deliver a life-saving product.
Girondi asserts that these powerful players prioritize profits over patient care, causing not only harm but leading to billions of dollars in unjust financial losses linked to inflated treatment costs.
The allegations compound a troubling trend in which innovative solutions are suppressed to protect lucrative pharmaceutical interests.
In revealing details of his fight, Girondi highlights the stark disparity in pricing between his treatment, projected at $800,000 per patient, versus Bluebird's exorbitant alternative, initially estimated at $750,000 but skyrocketed to $3.1 million due to circumvention tactics that Girondi alleges are rooted in corporate malfeasance.
Even more disturbingly, Girondi claims that some players engage in practices akin to organized crime, with the pharmaceutical industry paying over $4 billion in bribes to public officials over the past 20 years.
Such assertions raise critical questions about the integrity of regulatory processes designed to safeguard public health and remind Americans of the potential dangers posed by the intertwining of corporate greed and public health policy.
As Girondi continues his battle against these alleged injustices, he remains hopeful that the advancement of his gene therapy will soon enter clinical trials, potentially transforming the lives of thousands suffering from these debilitating diseases.
In a climate where innovation is so frequently stifled by those with vested interests, this case serves as a rallying cry for accountability and reform in the healthcare industry.
The ongoing saga underscores the importance of vigilance in supporting fair practices within healthcare, ultimately ensuring that patient well-being remains at the forefront of genetic and medical advancement.
Sources:
pjmedia.com
rumble.com
theepochtimes.com
Patrick Girondi, the founder of San Rocco Therapeutics (SRT), has launched a fierce campaign against corporate giants in Big Pharma, claiming that they are obstructing groundbreaking advances in gene therapy for sickle cell disease and thalassemia.
In a recent meeting with Health and Human Services Secretary Robert F. Kennedy Jr. and FDA officials, Girondi detailed a conspiracy to suppress his innovative and affordable gene therapy solutions—efforts which he argues have cost both lives and financial stability over the years.
According to Girondi, the industry's greed is jeopardizing the health of countless patients who could benefit from his treatments.
He accuses notable figures in the pharmaceutical sector, including former Bluebird Bio CEO Nick Leschly, of misappropriation and sabotaging SRT’s potential to deliver a life-saving product.
Girondi asserts that these powerful players prioritize profits over patient care, causing not only harm but leading to billions of dollars in unjust financial losses linked to inflated treatment costs.
The allegations compound a troubling trend in which innovative solutions are suppressed to protect lucrative pharmaceutical interests.
In revealing details of his fight, Girondi highlights the stark disparity in pricing between his treatment, projected at $800,000 per patient, versus Bluebird's exorbitant alternative, initially estimated at $750,000 but skyrocketed to $3.1 million due to circumvention tactics that Girondi alleges are rooted in corporate malfeasance.
Even more disturbingly, Girondi claims that some players engage in practices akin to organized crime, with the pharmaceutical industry paying over $4 billion in bribes to public officials over the past 20 years.
Such assertions raise critical questions about the integrity of regulatory processes designed to safeguard public health and remind Americans of the potential dangers posed by the intertwining of corporate greed and public health policy.
As Girondi continues his battle against these alleged injustices, he remains hopeful that the advancement of his gene therapy will soon enter clinical trials, potentially transforming the lives of thousands suffering from these debilitating diseases.
In a climate where innovation is so frequently stifled by those with vested interests, this case serves as a rallying cry for accountability and reform in the healthcare industry.
The ongoing saga underscores the importance of vigilance in supporting fair practices within healthcare, ultimately ensuring that patient well-being remains at the forefront of genetic and medical advancement.
Sources:
pjmedia.com
rumble.com
theepochtimes.com
Latest News